Full-Time

Senior Accountant

Revenue & Collaboration

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

70% in-office structure.

Category
Financial Accounting
Financial Analysis
Financial Planning
Accounting
Required Skills
SAP Products
Requirements
  • Bachelor’s degree in Accounting, Finance, Business Administration, or a related field
  • 2-4+ years of public accounting or combined public accounting and industry experience; biotechnology/pharmaceutical Industry experience is a plus
  • Strong knowledge of US GAAP, internal controls and managing a quarter-end close and reporting process
  • Knowledge of life science accounting transactions
  • Knowledge of ASC 606 revenue accounting for collaborative arrangements and product revenue
  • Possess strong SOX internal controls background and demonstrated ability to manage and drive a quarter-end close process fully compliant under SOX, is a plus
  • Experience with financial systems including SAP, Blackline, and Concur (or other AP or T&E systems); and Microsoft Suite of products
  • CPA and Big 4 public accounting firm experience preferred
Responsibilities
  • Assist in the monthly and quarterly revenue close and financial reporting process under the guidance of senior team members, acting with dynamic range to support both strategic and tactical accounting activities
  • Prepare monthly journal entries, account reconciliations, and variance analysis for areas including revenue, accounts receivable, and deferred revenue.ensuring accuracy and adherence to US GAAP
  • Monitor sales transaction flow from 3PL into Moderna ERP system, ensuring data integrity and accuracy to prioritize the platform and facilitate reliable reporting
  • Reconcile all data from 3PLs and the Revenue Management Managed Service provider related to product sales, chargebacks, prompt pay, and administrative fees, questioning convention as needed to resolve discrepancies and enhance reconciliation processes.
  • Assist in booking true-up journal entries related to Gross-To-Net balance sheet accruals for US Commercial, taking ownership and acting with an owner's mindset to maintain high standards of accuracy
  • Prepare monthly reporting related to product sales, including chargebacks, rebates, and administrative fees, pushing past possible to deliver clear, concise, and comprehensive reports
  • Support the billing process for third-party collaboration and partnership activities under the direction of senior accountants, aiming to remove viscosity in communication and ensure timely, accurate billing
  • Contribute to close process improvements as directed by the team to support timely SEC filing, pivoting fearlessly when faced with challenges or new information to optimize efficiency
  • Support department goals, including the implementation of accounting-related systems/applications and process improvements, digitizing where possible to enhance functionality and streamline operations
  • Support external financial audits and the SOX 404 audits, including preparing PBCs (prepared by client schedules) for the audits and our SEC filings, taking calculated risks to drive audit efficiency and reduce redundancies
  • Ensure close controls are properly performed and adequately supported with workpaper documentation as required under SOX, and meticulously documenting and supporting financial processes
  • Establish and maintain strong business partnerships with key counterparts, including FP&A, Program Managers, Procurement, and functional business owners, working to encourage collective action and foster a seamless cross-functional collaboration

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more direct and efficient way to instruct cells to produce therapeutic proteins. The company's goal is to improve patient outcomes by harnessing the power of mRNA technology to create effective treatments for a range of diseases.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's new plant in Shanghai expands its manufacturing and market presence in Asia.
  • The Victoria vaccine facility enhances Moderna's global production capacity.
  • Collaboration with OpenAI may enhance drug discovery and development processes.

What critics are saying

  • Legal challenges over mRNA technology could impact financial stability.
  • Hong Kong residents' vaccine reticence may affect market penetration.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company has developed one of the earliest effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious, rare, and autoimmune diseases.

Help us improve and share your feedback! Did you find this helpful?